Chimeric antigen receptor (CAR)-T cell therapy shows excellent potency against hematological malignancies. but it remains challenging to treat solid tumors. mainly because of a lack of appropriate antigenic targets and an immunosuppressive tumor microenvironment (TME). The checkpoint molecule programmed death-ligand 1 (PD-L1) is widely overexpressed in multiple tumor types. https://www.roneverhart.com/24-7-Series-Tactical-Softshell-Jacket/